Mehran Sugar Mills Limited (MRNS)

Feb 11, 2025 - MRNS was delisted (reason: acquired by Immedica)
0.5500
+0.0010 (0.09%)
Inactive · Last trade price on Feb 11, 2025
0.09%
Market Cap18.74M
Revenue (ttm)49.16M
Net Income (ttm)536,409
Shares Out 74.93M
EPS (ttm)0.01
PE Ratio34.60
Forward PEn/a
Dividend$0.01 (4.28%)
Ex-Dividend DateAug 4, 2025
Volume1,102,795
Open0.5500
Previous Close0.5500
Day's Range0.5490 - 0.5500
52-Week Range0.2200 - 10.5000
Beta0.40
AnalystsBuy
Price Target4.28 (+678.18%)
Earnings DateDec 18, 2025

About MRNS

Mehran Sugar Mills Limited manufactures and sells sugar and its by-products in Pakistan. The company offers white refined cane and brown sugar under the Sugarie and Chashnik brand names. It also provides sugar byproducts, such as molasses and bagasse. Mehran Sugar Mills Limited was incorporated in 1965 and is headquartered in Karachi, Pakistan. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 31, 2014
Employees 278
Stock Exchange NASDAQ
Ticker Symbol MRNS
Full Company Profile

Financial Performance

Financial numbers in PKR Financial Statements

Analyst Summary

According to 12 analysts, the average rating for MRNS stock is "Buy." The 12-month stock price target is $4.28, which is an increase of 678.18% from the latest price.

Price Target
$4.28
(678.18% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Marinus Pharmace...

9 months ago - Business Wire

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceuti...

10 months ago - Business Wire

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported ...

11 months ago - Business Wire

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced...

1 year ago - Business Wire

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today presented...

1 year ago - Business Wire

3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity

Micro-cap stocks can come in many shapes and sizes. Some might be once successful firms that lost their way and are looking to recover their prior glory.

Other symbols: AMPXLODE
1 year ago - Benzinga

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced...

1 year ago - Business Wire

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced...

1 year ago - Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced...

1 year ago - Business Wire

Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?

Marinus Pharmaceuticals MRNS is a micro-cap pharmaceutical stock with multiple Wall Street analysts seeing significant upside. Both Oppenheimer and Cantor Fitzgerald recently issued or reiterated mass...

1 year ago - Benzinga

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hostin...

1 year ago - Business Wire

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced...

1 year ago - Business Wire

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced...

1 year ago - Business Wire

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, will host an In...

1 year ago - Business Wire

Marinus Pharmaceuticals, Inc. (MRNS) Q2 2024 Earnings Call Transcript

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Sonya Weigle - Chief People and Investor Relations Officer Scott Braunstei...

1 year ago - Seeking Alpha

Pacific Defense Announces US Army CMFF Program Team

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense, a leading provider of Modular Open Systems Approach (MOSA) products and mission solutions, announced their team to compete for the U.S. Army's CMO...

Other symbols: MNMD
1 year ago - Business Wire

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported ...

1 year ago - Business Wire

Investors Are Invited To Participate In The Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASD...

1 year ago - Accesswire

MRNS Investors Have Opportunity To Join Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmace...

1 year ago - Accesswire

MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.

1 year ago - Business Wire

Marinus Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm Which Encourages Affected Investors To Initiate Discussions

LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceu...

1 year ago - Accesswire

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...

1 year ago - Business Wire

DEADLINE NEXT WEEK: Berger Montague Advises Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Investors to Contact the Firm Before August 5, 2024

PHILADELPHIA, July 29, 2024 (GLOBE NEWSWIRE) -- Attention Marinus Pharmaceuticals, Inc. (“Marinus” or the “Company”) (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed ag...

1 year ago - GlobeNewsWire

Marinus Pharmaceuticals Inc Is Being Probed By The Schall Law Firm Which Motivates Affected Investors To Begin Discussions

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceu...

1 year ago - Accesswire

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him Directly To Discuss Their Options If you suf...

1 year ago - PRNewsWire